Kintsugi develops voice biomarker infrastructure that analyzes short clips of free-form speech to detect signals consistent with depression and anxiety. The company targets risk-bearing health systems, payers, and capitated provider organizations that want to identify at-risk members earlier and close gaps in mental healthcare access.
Kintsugi's core technology processes brief, unstructured speech samples to predict the presence of signals consistent with current depressive episodes. The company positions this as a way to help health plans and providers screen members at scale without relying solely on traditional questionnaires. The Kintsugi Voice (KV) API is designed for integration with just a few lines of code, allowing care organizations to embed voice-based screening into existing workflows.
Kintsugi works with top payers and capitated health plans to identify at-risk members early, reduce costs, and improve outcomes. The product page is explicitly intended for professionals affiliated with health organizations and providers or payers investigating or currently using Kintsugi. This focus on risk-bearing entities reflects the company's mission to scale access to mental healthcare for all.
Kintsugi's peer-reviewed study on Voice AI was published in the Annals of Family Medicine, providing external validation of its approach. The company was also named to Forbes 50 AI, a recognition that may matter to health system decision-makers evaluating vendors. These milestones suggest Kintsugi has moved beyond early-stage development, though the underlying device remains investigational.
Kintsugi states that its product team works directly with clients to set teams up for success, including an implementation plan. The API-first design means integration can be lightweight, but the company still offers hands-on support for health organizations that need help deploying voice biomarker screening across member populations.
Kintsugi is an investigational device not yet cleared by the FDA for any particular use. The company explicitly states that Kintsugi is not a substitute for a clinician diagnosis and should not be used to make medical decisions outside of clinician supervision. Any organization considering Kintsugi should treat it as a screening aid rather than a diagnostic tool, and should plan for clinician oversight in any care pathway that uses its output.
For payers and capitated health plans, Kintsugi offers a way to surface members who might otherwise go unnoticed until a crisis. By analyzing free-form speech, the system may reduce the burden on patients and providers compared to longer assessments. The company's mission—ensuring everyone who needs mental healthcare has access to the right care at the right time—frames the technology as a tool for population health rather than a standalone clinical solution.